Haleon (NYSE:HLN) Announces Quarterly Earnings Results

Haleon (NYSE:HLN) posted its earnings results on Thursday. The company reported $0.05 EPS for the quarter, Zacks reports. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion.

Haleon Trading Up 3.9 %

NYSE HLN opened at $10.18 on Friday. Haleon has a one year low of $7.89 and a one year high of $10.80. The company’s 50 day moving average price is $9.59 and its 200 day moving average price is $9.83. The firm has a market capitalization of $46.06 billion, a price-to-earnings ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.28. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HLN. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.